Obicetrapib Cuts Coronary Events 32% in High-Risk Heart Patients
A pooled analysis of 2,884 patients finds obicetrapib significantly reduces coronary events after 6 months, with striking lipid improvements.
Summary
Obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, was tested in nearly 3,000 high-risk cardiovascular patients in a pooled analysis. The drug produced dramatic lipid improvements — cutting LDL-C by 38%, lowering Lp(a) by 33%, and raising HDL-C by an extraordinary 140%. While the primary cardiovascular event endpoint narrowly missed statistical significance overall, coronary events were significantly reduced by 32% over the full year, with the benefit becoming even stronger in the second six months (55% risk reduction). These findings suggest obicetrapib may offer meaningful cardiovascular protection, especially with longer treatment. Industry funding and the short one-year follow-up period are important caveats to consider when interpreting results.
Detailed Summary
Cardiovascular disease remains the leading cause of death globally, and despite existing therapies, many high-risk patients still experience events. A new cholesterol-modifying drug called obicetrapib — a CETP inhibitor — has shown promising results in a pooled analysis published in the Journal of the American College of Cardiology, raising hopes for an additional tool in the lipid-lowering arsenal.
Researchers pooled data from the BROOKLYN and BROADWAY trials, enrolling 2,884 patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Participants received either 10 mg of obicetrapib or placebo daily for one year. The analysis examined rates of major adverse cardiovascular events (MACE) and the relationship between achieved lipid levels and outcomes.
Obicetrapib produced remarkable lipid changes: LDL-C fell by 37.8%, ApoB by 21.7%, non-HDL-C by 32.4%, and Lp(a) by 32.5%, while HDL-C surged by 140%. The overall MACE rate favored obicetrapib (3.9% vs. 5.0%; HR 0.77) but did not reach significance. However, a composite of coronary death, MI, or revascularization showed a significant 32% reduction (HR 0.68; p=0.048), with the effect intensifying in months 7–12 (HR 0.45; p=0.003). Achieved lipid levels across all measures were independently associated with event rates.
These results suggest obicetrapib's cardiovascular benefits strengthen over time — a pattern consistent with how lipid-lowering therapies generally work. The drug's ability to simultaneously lower LDL-C, Lp(a), and ApoB while dramatically raising HDL-C sets it apart from statins and PCSK9 inhibitors.
Key caveats temper enthusiasm. The trials were industry-sponsored by NewAmsterdam Pharma, with multiple authors holding stock or consulting relationships. The one-year follow-up is short for establishing durable cardiovascular benefit, the primary MACE endpoint was not statistically significant, and this was a pooled rather than pre-specified outcomes analysis. The pivotal PREVAIL outcomes trial will be critical for confirmation.
Key Findings
- Obicetrapib reduced LDL-C by 38% and raised HDL-C by 140% versus placebo over one year.
- Lp(a) was lowered by 32.5% — a clinically meaningful reduction for a notoriously hard-to-treat risk factor.
- Coronary death, MI, or revascularization was reduced by 32% overall (HR 0.68; p=0.048).
- In months 7–12, coronary event risk fell by 55% (HR 0.45; p=0.003), suggesting growing benefit over time.
- Achieved levels of LDL-C, ApoB, Lp(a), and HDL-C were all independently linked to event rates.
Methodology
This was a pooled analysis of two randomized, placebo-controlled trials (BROOKLYN and BROADWAY) enrolling 2,884 patients with HeFH or ASCVD treated for 365 days. Cardiovascular event rates and lipid associations were examined as pre-specified and exploratory endpoints. The pooled design increases statistical power but was not a single pre-specified outcomes trial.
Study Limitations
This summary is based on the abstract only, as the full text was not available; detailed methodology, subgroup analyses, and safety data could not be reviewed. The trials were industry-sponsored (NewAmsterdam Pharma), and several authors hold equity or consulting relationships with the company, introducing potential bias. The one-year follow-up is short, the primary MACE endpoint did not achieve statistical significance, and this is a pooled rather than a single pre-specified cardiovascular outcomes trial.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.